Alzamend Neuro Inc. Stock
-
Your prediction
Alzamend Neuro Inc. Stock
Pros and Cons of Alzamend Neuro Inc. in the next few years
Pros
Cons
News
![Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel: https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy92Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cef2f54932d3c409039cc4fa6fab82e7f5480941/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg?locale=us)
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar
![Alzamend Neuro Announces Initial Closing of Private Placement : https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy92Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cef2f54932d3c409039cc4fa6fab82e7f5480941/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg?locale=us)
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar
![Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million: https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy92Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cef2f54932d3c409039cc4fa6fab82e7f5480941/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg?locale=us)
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar